Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin glargine for elderly patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
ChiCTR-IPC-15006339Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- May 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of exenatide and insulin glargine in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Markers of hepatic function, Controlled attenuation parameter and 3 more. Planned start May 2015; status: not yet recruiting.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR-IPC-15006339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPC-15006339.